AlphaYou
Overview
Key stats
Fundamentals Sep 10- Open
- $9.09
- 52-wk high
- $16.19
- High
- $9.22
- 52-wk low
- $5.46
- Low
- $8.86
- Prev close
- $9.20
- Mkt cap
- $578.3M
- Volume
- 1.07M
- Beta
- 0.93
- P/S
- 3.3x
- P/B
- 8.2x
- Profit margin
- -112.6%
- Op margin
- +27.1%
- ROE
- -137.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
Earnings
Earnings came in $0.31 a share above what analysts expected.
Earnings per share
$0.12 expected
What the street expects next
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $29.7M | $30.3M | $6.4M | $108.0M |
| Cost of what it sold | $61.8M | $5.9M | $11.1M | $1.0M |
| Gross profit | -$32.1M | $24.4M | -$4.7M | $107.0M |
| What it spent | ||||
| Research and development | $56.1M | $59.6M | $57.3M | $56.1M |
| Sales and admin | $20.3M | $22.4M | $21.3M | $21.6M |
| Other operating costs | -$56.0M | — | — | — |
| Total operating expenses | $20.3M | $82.0M | $78.7M | $77.7M |
| What was left | ||||
| Operating profit | -$52.4M | -$57.6M | -$83.4M | $29.3M |
| Interest on debt | $13.2M | $12.3M | $8.7M | $7.8M |
| Profit before tax | -$61.9M | -$67.1M | -$90.1M | $22.7M |
| Net profit | -$61.9M | -$67.1M | -$90.1M | $22.7M |
| EBITDA | -$44.9M | -$51.0M | -$77.5M | $34.3M |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bearish
Tone of tracked coverage
REGENXBIO CFO Mitchell Chan Reports Tax-Driven Share Withholding on RSU Vesting
NeutralSep 4Regenxbio stock surges on director share purchases
BullishAug 28People on the Move: Greg Ciongoli Joins REGENXBIO’s Board of Directors
BullishAug 28Regenxbio director Ciongoli buys $949,381 in RGNX stock
NeutralAug 28REGENXBIO Director Gregory Ciongoli Discloses Multiple Stock Purchases and Option Grant in August 2026
Leans bullishAug 28REGENXBIO (RGNX) grants $550K equity to new board hire
NeutralAug 25Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
BearishAug 25RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy
BearishAug 25
Macro
11 macro signals shaping RGNX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results